Summary This United States community study evaluated the combination of daratumumab,
bortezomib, cyclophosphamide and dexamethasone (D‐VCd) in newly diagnosed multiple …

Outside of clinical trials, experience with daratumumab‐based combination therapies
(DCTs) using bortezomib (V)/lenalidomide (R)/pomalidomide (P), and dexamethasone (d) in …

LBA4 Background: Daratumumab (D), a human anti-CD38 IgGκ mAb, induces deep and
durable responses with a favorable safety profile in RRMM pts. We report a pre-specified …

Background In the phase III CASTOR study in relapsed or refractory multiple myeloma,
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …

Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical
activity in combination with bortezomib and dexamethasone versus bortezomib and …

The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab
plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory …

Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …

Background Daratumumab plus bortezomib/dexamethasone (D-Vd) significantly improved
outcomes versus Vd in patients with relapsed or refractory multiple myeloma (RRMM) in the …

Background Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces
direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy …

Background The combination of bortezomib, melphalan, and prednisone is a standard
treatment for patients with newly diagnosed multiple myeloma who are ineligible for …